25th November 2019
Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs is pleased to announce a placing to raise £1.25 million before expenses of £77,000 (the “Placing”) via the issue of 17,857,142 new Ordinary Shares of 0.1p each in the Group at 7p per share (“Placing Shares”). Download News